CAR-T therapy is showing promise in treating patients with lenalidomide-refractory multiple myeloma (MM). The results come from patients with lenalidomide-refractory MM treated in the CARTITUDE-4 trial after 1 to 3 lines of prior therapy.
TRANSCEND-NHL-001 Trial Update
The clinical director of lymphoma services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial, offering insights into the long-term outcomes of CAR-T cell therapy in lymphoma patients.
Bendamustine as Fludarabine Alternative
In response to fludarabine shortages, research indicates that lymphodepletion with bendamustine is an effective alternative for patients with large B-cell lymphoma undergoing CD19-directed CAR T-cell therapy. This finding provides a crucial option for clinicians facing drug supply challenges.
Exa-cel Data Update
The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute presented the latest data update from the CLIMB SCD-121 trial evaluating exa-cel, offering new insights into its efficacy and safety profile.
Tabelecleucel for EBV-Associated Lymphoproliferative Disease
With an FDA decision anticipated in January, tabelecleucel has demonstrated sustained safety and efficacy with extended follow-up in treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease, reinforcing its potential as a therapeutic option.
